Newton, MA, United States of America

Melissa Marie Vasbinder

USPTO Granted Patents = 11 

 

Average Co-Inventor Count = 4.2

ph-index = 3

Forward Citations = 26(Granted Patents)


Location History:

  • Cambridge, MA (US) (2022)
  • Newton, MA (US) (2020 - 2024)

Company Filing History:


Years Active: 2020-2025

where 'Filed Patents' based on already Granted Patents

11 patents (USPTO):

Title: Melissa Marie Vasbinder: Innovator in Cancer Treatment

Introduction

Melissa Marie Vasbinder is a prominent inventor based in Newton, MA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of pharmaceutical compounds. With a total of 11 patents to her name, she continues to push the boundaries of medical science.

Latest Patents

Among her latest patents is the invention titled "Solid forms of a PARP7 inhibitor." This invention relates to solid forms of the poly(ADP-ribose) polymerase 7 (PARP7) inhibitor, which is useful in the treatment of cancer. Another notable patent is "Quinazolinones as PARP14 inhibitors," which focuses on quinazolinones and related compounds that serve as inhibitors of PARP14, also aimed at treating cancer and inflammatory diseases.

Career Highlights

Melissa is currently associated with Ribon Therapeutics, Inc., where she applies her expertise in drug development. Her work has been instrumental in advancing therapeutic options for patients suffering from cancer.

Collaborations

Throughout her career, Melissa has collaborated with notable colleagues, including Kevin Wayne Kuntz and Laurie B Schenkel. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Melissa Marie Vasbinder stands out as a dedicated inventor whose work is making a significant impact in the field of cancer treatment. Her innovative patents and collaborations reflect her commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…